FY2025 EPS Forecast for Alpha Tau Medical Reduced by Analyst

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Equities researchers at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Alpha Tau Medical in a report issued on Monday, March 17th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.53) for the year, down from their previous forecast of ($0.50). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13).

Alpha Tau Medical Price Performance

NASDAQ DRTS opened at $2.62 on Wednesday. The stock has a market capitalization of $183.20 million, a price-to-earnings ratio of -6.09 and a beta of 0.87. Alpha Tau Medical has a 1-year low of $1.75 and a 1-year high of $4.39. The business’s fifty day moving average price is $3.25 and its 200-day moving average price is $2.80.

Institutional Trading of Alpha Tau Medical

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after acquiring an additional 26,800 shares during the period. Northern Trust Corp lifted its position in Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after purchasing an additional 25,770 shares in the last quarter. Finally, Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after purchasing an additional 7,189 shares during the period. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.